Form 4: Ginkgo Bioworks Insider Trades: CFO Transactions

Steven P. Coen, CFO of Ginkgo Bioworks Holdings, Inc., reported transactions involving Class A Common Stock and Restricted Stock Units.

Summary

• Steven P. Coen, Chief Financial Officer of Ginkgo Bioworks Holdings, Inc. (DNA), reported transactions on May 21, 2026, and May 22, 2026.
• On May 21, 2026, 587 shares of Class A Common Stock were acquired via vesting of Restricted Stock Units (RSUs) and 156 shares of Class A Common Stock were also acquired via RSU vesting.
• On May 22, 2026, 307 shares of Class A Common Stock were disposed of at a price of $8.334 per share.
• These disposals were made to cover tax withholding obligations related to the vesting of restricted stock and/or RSUs, as permitted by the company's equity incentive plans.
• Following these transactions, Mr. Coen beneficially owns 50,704 shares of Class A Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the reported transactions are standard insider activities related to equity compensation and tax obligations, rather than discretionary trading.

Positives

• Acquisition of shares through RSU vesting indicates continued equity compensation and potential alignment with company performance.
• The company's equity incentive plans allow for 'sell to cover' transactions to manage tax obligations, which is a standard and practical approach.

Negatives

• Disposal of 307 shares to cover tax withholding obligations represents a reduction in direct beneficial ownership, albeit for a necessary purpose.

Risks

• The 'sell to cover' transactions, while standard, do reduce the reporting person's direct holdings, which could be perceived negatively by some investors if not understood in context.
• Future vesting schedules for RSUs could lead to further 'sell to cover' transactions, potentially impacting the reporting person's net holdings.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person.
• The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a 'sell to cover' transaction.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The 'sell to cover' strategy for tax withholding is common practice across the biotechnology and synthetic biology sectors, particularly when employees receive equity compensation.

Stakeholder Impact

• Shareholders: The transactions are standard for equity compensation and tax management, with no indication of discretionary selling pressure from the CFO.
• Employees: The 'sell to cover' mechanism highlights the company's approach to managing equity-based compensation and associated tax liabilities.
• Management: The filing confirms the CFO's continued equity holdings, albeit with adjustments for tax obligations.

Next Steps

• Continued monitoring of insider transactions for any discretionary trading patterns.
• Tracking future RSU vesting schedules and potential 'sell to cover' activities.

Key Dates

Keywords

Ginkgo Bioworks, DNA, Form 4, Insider Trading, Steven P. Coen, CFO, Restricted Stock Units, RSU Vesting, Class A Common Stock, Tax Withholding, Securities Exchange Act